Boston Scientific has received expanded indication approval for its Vercise Deep Brain Stimulation (DBS) System in Europe. Previously indicated only for Parkinson’s patients, the Vercise can now be used to treat intractable primary and secondary dystonia, a neurological movement disorder resulting in repetitive movements and twisting caused by prolonged muscle contractions.
The Vercise DBS features Multiple Independent Current Control (MICC) technology, allowing the device to send electric current to each contact on the lead separately to help regulate signaling while keeping the side effects of stimulation as low as possible. From the press release:
“Historically, treatment of secondary dystonia has been challenging and efficacy was typically incomplete and partially limited by side effects. The Vercise DBS system represents an advancement in dystonia care by providing more flexible and unique programming options for targeted deep brain stimulation tailored to each individual,” said Prof. Dr. Andrea Kühn.
“The device itself is designed to offer additional patient benefits including the longest battery life available for DBS and the smallest implanted stimulator footprint, especially important for our young patients,” said Dr. Gerd-Helge Schneider.